The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Dihexa Peptide Therapy Memory & Cognition Beverly Hills FDA approvals February 2026 FDA Alerts: Ophthalmology Drug and Device Approvals Ophthalmology Advisor FDA Removes 12 Peptides from 503A Category 2 Newtropin FDA Tracker for Cell and Gene Therapies in 2026 Alliance for Regenerative Medicine posted on the topic LinkedIn